CC-42344 - Influenza A PB2 Inhibitor
Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
---|---|---|---|---|---|---|---|
Pandemic Influenza A | CC-42344 PB2 Inhibitor |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
CC-42344, our lead molecule, binds to a highly conserved PB2 site of influenza polymerase complex and exhibits a novel mechanism of action which inhibits replication. CC-42344 has shown excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu® resistant strains, and shows favorable pharmacokinetic and drug resistance profiles. CC-42344 is currently being evaluated in preclinical IND-enabling studies for the treatment of influenza.